A pilot study assessing the effectiveness of oral Propranolol in preventing epistasis in patients with Hereditary Haemorrhagic Telangiectasia.

Not Applicable

• Conditions: Hereditary Haemorrhagic Telangiectasia; Human Genetics and Inherited Disorders - Other human genetics and inherited disorders; Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system

• Registration Number: ACTRN12619001020178
• Lead Sponsor: Royal brisbane and Women's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-07-16
• Last Update Posted: 22 July 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Participants with a diagnosis of HHT according to curacao criteria score of >4
Participants with an Epistaxis severity score of >4 despite conventional treatment

Exclusion Criteria

Absolute contraindication to Propranolol e.g. Bradycardia
Pregnancy or breast feeding
Planned surgical intervention for epistaxis control
Deemed by cardiologist as unsuitable for taking Propranolol medication

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in Epistasis. Measured using Epistaxis scoring sheet.[6 months post baseline]

Secondary Outcome Measures

Name	Time	Method
Change in Blood transfusions administered to patient. Recorded in CRF but also captured on Epistaxis scoring sheet.[6 Months post baseline];Change in Quality of Life. This will be measured by using the SF36 questionnaire before and after treatment.[Baseline and 6 months post baseline.]